keyword
MENU ▼
Read by QxMD icon Read
search

"phase 3" cancer

keyword
https://www.readbyqxmd.com/read/29784134/a-five-phase-process-model-describing-the-return-to-sustainable-work-of-persons-who-survived-cancer-a-qualitative-study
#1
Birgit Brusletto, Steffen Torp, Camilla Martha Ihlebæk, Hege Forbech Vinje
PURPOSE: We investigated persons who survived cancer (PSC) and their experiences in returning to sustainable work. METHODS: Videotaped, qualitative, in-depth interviews with previous cancer patients were analyzed directly using "Interpretative Phenomenological Analysis" (IPA). Four men and four women aged 42-59 years participated. Mean time since last treatment was nine years. All participants had worked for more than 3 years when interviewed. An advisory team of seven members with diverse cancer experiences contributed as co-researchers...
June 2018: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/29779695/successful-treatment-switch-from-lenvatinib-to-sorafenib-in-a-patient-with-radioactive-iodine-refractory-differentiated-thyroid-cancer-intolerant-to-lenvatinib-due-to-severe-proteinuria
#2
Hideaki Goto, Naomi Kiyota, Naoki Otsuki, Yoshinori Imamura, Naoko Chayahara, Hirotaka Suto, Yoshiaki Nagatani, Masanori Toyoda, Toru Mukohara, Ken-Ichi Nibu, Toshihiko Kasahara, Yasuhiro Ito, Akihiro Miya, Mitsuyoshi Hirokawa, Akira Miyauchi, Hironobu Minami
Sorafenib and lenvatinib showed efficacy for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) in pivotal phase 3 clinical trials. Although the efficacy of lenvatinib in patients who received previous treatment with multi-target kinase inhibitors (m-TKIs), including sorafenib, was reported, the efficacy of sorafenib in patients who previously received lenvatinib remains unknown. A 75-year-old woman diagnosed as RAI-refractory poorly differentiated carcinoma with multiple lung metastases and started treatment with lenvatinib...
May 17, 2018: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/29774521/patient-reported-outcomes-of-multiple-myeloma-patients-treated-with-panobinostat-after-%C3%A2-2-lines-of-therapy-based-on-the-international-phase-3-randomized-double-blind-placebo-controlled-panorama-1-trial
#3
Paul G Richardson, Robert L Schlossman, Anuja N Roy, Ashok Panneerselvam, Suddhasatta Acharyya, Monika Sopala, Sagar Lonial
The phase 3 PANORAMA-1 trial led to regulatory approvals of panobinostat (PAN) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of multiple myeloma after ≥2 prior regimens, including BTZ and an immunomodulatory drug. Patient-reported outcomes (PROs) were assessed in PANORAMA-1, with data available for 73 patients in the PAN + BTZ + DEX arm and 74 patients in the placebo (PBO) + BTZ + DEX arm. Per the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), global health status/quality of life (QoL) scores initially declined with PAN + BTZ + DEX during the first 24 weeks before approaching baseline scores and remaining steady during the next 24 weeks, with no difference between arms at Week 48...
May 17, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29773662/validation-of-the-16-gene-recurrence-score-in-patients-with-locoregional-high-risk-renal-cell-carcinoma-from-a-phase-3-trial-of-adjuvant-sunitinib
#4
Brian I Rini, Bernard Escudier, Jean-Francois Martini, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D Goddard, Phillip G Febbo, Rachel Li, Xun Lin, Olga Valota, Michael Staehler, Robert J Motzer, Alain Ravaud
PURPOSE: Adjuvant sunitinib prolonged disease-free survival (DFS) (hazard ratio [HR] 0.76) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov NCT00375674). The 16-gene Recurrence Score (RS) assay was previously developed and validated to estimate risk for disease recurrence in patients with RCC post-nephrectomy. This analysis further validated the prognostic value of RS assay in patients from S-TRAC and explored association of RS results with prediction of sunitinib benefit...
May 17, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29770225/quality-of-life-of-irradiated-brain-tumor-survivors-treated-with-donepezil-or-placebo-results-of-the-wfu-ccop-research-base-protocol-91105
#5
Michelle J Naughton, L Douglas Case, Ann Peiffer, Michael Chan, Volker Stieber, Dennis Moore, Steven Falchuk, James Piephoff, William Edenfield, Jeffrey Giguere, Monica Loghin, Edward G Shaw, Stephen R Rapp
Background: The health-related quality of life (HRQL) and fatigue of brain cancer survivors treated with donepezil or placebo for cognitive symptoms after radiation therapy were examined. Methods: One hundred ninety-eight patients who completed >30 Gy fractionated whole or partial brain irradiation at least 6 months prior to enrollment were randomized to either placebo or donepezil (5 mg for 6 weeks followed by 10 mg for 18 weeks) in a phase 3 trial. A neurocognitive battery, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue, was administered at baseline, 12 weeks, and 24 weeks...
May 2018: Neuro-oncology Practice
https://www.readbyqxmd.com/read/29767677/randomized-phase-3-study-of-docetaxel-plus-bavituximab-in-previously-treated-advanced-non-squamous-non-small-cell-lung-cancer
#6
D E Gerber, L Horn, M Boyer, R Sanborn, R Natale, R Palmero, P Bidoli, I Bondarenko, P Germonpre, D Ghizdavescu, A Kotsakis, H Lena, G Losonczy, K Park, W-C Su, M Tang, J Lai, N L Kallinteris, J S Shan, M Reck, D R Spigel
Background: Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an anti-tumor immune response. This phase 3 trial determined the efficacy of bavituximab combined with docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Patients and Methods: Key eligibility criteria included advanced non-squamous NSCLC with disease progression after treatment with platinum-based doublet chemotherapy, evidence of disease control after at least two cycles of first-line therapy, presence of measurable disease, ECOG performance status 0 or 1, adequate bone marrow and organ function, and no recent history of clinically significant bleeding...
May 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29766456/prognostic-role-for-the-derived-neutrophil-to-lymphocyte-ratio-in-early-breast-cancer-a-geicam-9906-substudy
#7
A J Templeton, Á Rodríguez-Lescure, A Ruíz, E Alba, L Calvo, M Ruíz-Borrego, A Santaballa, C A Rodríguez, C Crespo, M Ramos, J M Gracia-Marco, A Lluch, I Álvarez, M I Casas, M Sánchez-Aragó, R Caballero, E Carrasco, E Amir, M Martin, A Ocaña
PURPOSE: Elevated markers of host inflammation, a hallmark of cancer, have been associated with worse outcomes in several solid tumors. Here, we explore the prognostic role of the derived neutrophil-to-lymphocyte ratio (dNLR), across different tumor subtypes, in patients with early breast cancer. PATIENTS AND METHODS: This was a retrospective analysis of 1246 patients with lymph node-positive, operable early breast cancer enrolled in the GEICAM/9906 trial, a multicenter randomized phase 3 study evaluating adjuvant chemotherapy...
May 15, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29753703/ngr-htnf-in-combination-with-best-investigator-choice-in-previously-treated-malignant-pleural-mesothelioma-ngr015-a-randomised-double-blind-placebo-controlled-phase-3-trial
#8
Vanesa Gregorc, Rabab M Gaafar, Adolfo Favaretto, Francesco Grossi, Jacek Jassem, Andreas Polychronis, Paolo Bidoli, Marcello Tiseo, Riyaz Shah, Paul Taylor, Silvia Novello, Alberto Muzio, Alessandra Bearz, Laurent Greillier, Floriana Fontana, Giulia Salini, Antonio Lambiase, Mary O'Brien
BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer with highly vascularised tumours. It has poor prognosis and few treatment options after failure of first-line chemotherapy. NGR-hTNF is a vascular-targeting drug that increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment. In this trial, we aimed to investigate the efficacy and safety of NGR-hTNF in patients with malignant pleural mesothelioma who had progressed during or after a first-line treatment...
May 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29752332/prolonged-duration-of-response-in-lenvatinib-responders-with-thyroid-cancer
#9
Andrew G Gianoukakis, Corina E Dutcus, Nicolas Batty, Matthew Guo, Mahadi Baig
We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled phase 3 study, patients ≥18 years old with measurable, pathologically confirmed RR-DTC with independent radiologic confirmation of disease progression within the previous 13 months were randomized 2:1 to oral lenvatinib 24 mg/day or placebo. The main outcome measures for this analysis are DOR and progression-free survival (PFS)...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29739753/health-related-quality-of-life-in-adults-with-relapsed-refractory-acute-lymphoblastic-leukemia-treated-with-blinatumomab
#10
Max S Topp, Zachary Zimmerman, Paul Cannell, Hervé Dombret, Johan Maertens, Anthony Stein, Janet Franklin, Qui Tran, Ze Cong, Andre C Schuh
In the phase 3 TOWER study, blinatumomab significantly improved overall survival in adults with relapsed or refractory (R/R) Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) relative to standard-of-care chemotherapy. A secondary objective of this study was to assess the impact of blinatumomab on health-related quality of life (HRQL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). This analysis included the 342 of 405 randomized patients for whom baseline and ≥1 post-baseline result were available in any EORTC multi-item scale or single-item measure...
May 8, 2018: Blood
https://www.readbyqxmd.com/read/29738336/in-vitro-antitumor-activity-of-new-quaternary-phosphonium-salts-derivatives-of-3-hydroxypyridine
#11
Alfiya G Iksanova, Raylya R Gabbasova, Tatyana V Kupriyanova, Almaz A Akhunzyanov, Michail V Pugachev, Ruzalia M Vafiva, Nikita V Shtyrlin, Konstantin V Balakin, Yurii G Shtyrlin
This work presents the results of in-vitro biological activity studies of three novel anticancer agents, phosphonium salts based on the 3-hydroxypyridine scaffold, including one derivative of 4-deoxypyridoxine. Proliferation and viability of cells treated with these compounds was assessed by the colony formation and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Effects of the compounds on apoptosis and cell cycle were studied by flow cytometry using annexin V-FITC/propidium iodide and propidium iodide staining, respectively...
May 5, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29736669/a-propensity-score-matched-comparison-of-robotic-versus-laparoscopic-gastrectomy-for-gastric-cancer-oncological-cost-and-surgical-stress-analysis
#12
Jun Lu, Hua-Long Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ze-Ning Huang, Chang-Ming Huang, Chao-Hui Zheng
BACKGROUND: Robotic-assisted gastrectomy (RAG) has been rapidly adopted for gastric cancer (GC) treatment. However, whether RAG provides any significant outcome/cost advantages over laparoscopy-assisted gastrectomy (LAG) for the experienced laparoscopist remains unclear. METHODS: A retrospective review of a prospectively collected database identified 768 consecutive patients who underwent either RAG (n = 103) or LAG (n = 667) for GC between July 2016 and June 2017 at a large center...
May 7, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29733511/lenvatinib-inhibits-angiogenesis-and-tumor-fibroblast-growth-factor-signaling-pathways-in-human-hepatocellular-carcinoma-models
#13
Masahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, Megumi Ikemori-Kawada, Yukinori Minoshima, Yasuhiro Funahashi, Junji Matsui
Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs), recently demonstrated a treatment effect on overall survival by statistical confirmation of noninferiority to sorafenib in a phase 3 study of uHCC. Here, we investigated mechanisms underlying the antitumor activity of lenvatinib in preclinical HCC models...
May 7, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29731919/elevated-growth-differentiating-factor-15-expression-predicts-long-term-benefit-of-docetaxel-cisplatin-and-5-fluorouracil-induction-chemotherapy-in-patients-with-oral-cancer
#14
Xiao Tang, Yong-Jie Hu, Wu-Tong Ju, Yong Fu, Wen-Wen Sun, Ying Liu, Yi-Ran Tan, Li-Zhen Wang, Jiang Li, Yao-Yao Tu, Chen-Ping Zhang, Zhi-Yuan Zhang, Lai-Ping Zhong
Our previous phase 3 trial (NCT01542931) failed to demonstrate improved survival when docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy was introduced prior to surgery and postoperative radiotherapy in patients with locally advanced oral squamous cell carcinoma (OSCC). The aim of the present study was to investigate the long-term predictive value of GDF15 expression for potential personalized treatment strategies in OSCC. A total of 256 patients with stage III/IVA OSCC from our phase 3 trial were enrolled in the present study...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29730461/evolution-of-checkpoint-inhibitors-for-the-treatment-of-metastatic-gastric-cancers-current-status-and-future-perspectives
#15
REVIEW
Julien Taieb, Markus Moehler, Narikazu Boku, Jaffer A Ajani, Eduardo Yañez Ruiz, Min-Hee Ryu, Silke Guenther, Vikram Chand, Yung-Jue Bang
BACKGROUND: Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC. METHODS: Searches for studies of immunotherapy in GC/GEJC were performed using PubMed, ClinicalTrials...
April 22, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29729562/reporting-of-patient-characteristics-and-stratification-factors-in-phase-3-trials-investigating-first-line-systemic-treatment-of-metastatic-colorectal-cancer-a-systematic-review
#16
REVIEW
Kaitlyn K H Goey, Remi Mahmoud, Halfdan Sørbye, Bengt Glimelius, Claus-Henning Köhne, Daniel J Sargent, Cornelis J A Punt, Martijn G H van Oijen, Miriam Koopman
BACKGROUND: Patient characteristics and stratification factors are important factors influencing trial outcomes. Uniform reporting on these parameters would facilitate cross-study comparisons and extrapolation of trial results to clinical practice. In 2007, standardisation on patient characteristics reporting and stratification in metastatic colorectal cancer (mCRC) trials was proposed. We investigated the reporting of prognostic factors and implementation of this proposal in mCRC trials published from 2005 to 2016...
May 2, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29727313/nivolumab-in-the-treatment-of-metastatic-renal-cell-carcinoma-a-cost-utility-analysis
#17
Jacques Raphael, Zhuolu Sun, Georg A Bjarnason, Joelle Helou, Beate Sander, David M Naimark
INTRODUCTION: Nivolumab improves overall survival and health-related quality of life compared with everolimus in metastatic renal cell carcinoma (mRCC). This study assesses the cost-utility of nivolumab from the Canadian health care payer perspective. MATERIALS AND METHODS: To evaluate the cost-utility of nivolumab, a Markov cohort model that incorporated data from the phase 3 CheckMate-025 trial and other sources was developed. The incremental cost per quality-adjusted life month (QALM) gained for nivolumab was calculated...
May 4, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29722737/role-of-immune-checkpoint-inhibitors-in-small-cell-lung-cancer
#18
Maryann R Cooper, Abdullah M Alrajhi, Cheryl R Durand
BACKGROUND: Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancer diagnoses each year. SCLC is characterized by a rapid doubling time, early metastatic spread, and an unfavorable prognosis overall. AREAS OF UNCERTAINTY: Most patients with SCLC will respond to initial treatment; however, the majority will experience a disease recurrence and response to second-line therapies is poor. Immune checkpoint inhibitors may be an option given the success in other diseases...
May 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29721850/exposure-response-relationship-for-ramucirumab-from-the-randomized-double-blind-phase-3-revel-trial-docetaxel-versus-docetaxel-plus-ramucirumab-in-second-line-treatment-of-metastatic-non-small-cell-lung-cancer
#19
Egbert F Smit, Edward B Garon, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B Cohen, Ling Gao, Lisa M O'Brien, Pablo Lee, Annamaria Zimmermann, David R Ferry, Allen S Melemed, Maurice Pérol
PURPOSE: Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS: Patients received ramucirumab (10 mg/kg) or placebo plus docetaxel (75 mg/m2 ) every 3 weeks. Pharmacokinetic samples were collected. A population pharmacokinetic analysis predicted ramucirumab minimum concentration after first-dose administration (Cmin,1 ) and average concentration at steady state (Cave,ss )...
May 2, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29718095/neoadjuvant-rectal-score-as-individual-level-surrogate-for-disease-free-survival-in-rectal-cancer-in-the-cao-aro-aio-04-randomized-phase-3-trial
#20
E Fokas, R Fietkau, A Hartmann, W Hohenberger, R Grützmann, M Ghadimi, T Liersch, P Ströbel, G G Grabenbauer, U Graeven, R-D Hofheinz, C-H Köhne, C Wittekind, R Sauer, M Kaufmann, T Hothorn, C Rödel
BACKGROUND: Surrogate endpoints in rectal cancer after preoperative chemoradiation are lacking as their statistical validation poses major challenges, including confirmation based on large phase 3 trials. We examined the prognostic role and individual-level surrogacy of neoadjuvant rectal (NAR) score that incorporates weighted cT, ypT and ypN categories for disease-free survival (DFS) in 1191 patients with rectal carcinoma treated within the CAO/ARO/AIO-04 phase 3 trial. PATIENTS AND METHODS: Cox regression models adjusted for treatment arm, resection status, and NAR score were used in multivariable analysis...
April 27, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
91260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"